Catalio Capital Management, a leading venture capital firm focused on healthcare and biotechnology, has successfully closed its fourth venture fund, Fund IV, raising more than $400 million. This significant milestone, announced on July 1, 2025, underscores the firm’s ongoing commitment to driving innovation in the biomedical sector. Backed by prominent investors, including KKR & Co., Catalio continues to position itself as a key player in funding breakthrough technologies.
The new fund, slightly larger than its predecessor, will target innovative healthcare companies and startups with the potential to reshape the industry. Catalio has already made 16 investments from Fund IV, signaling a proactive approach to identifying and supporting promising ventures. The firm’s strategy focuses on bridging the gap between scientific discovery and market impact.
Founded with a mission to accelerate advancements in medicine, Catalio Capital has built a reputation for backing biotech startups that address critical unmet needs. The firm’s portfolio spans a range of cutting-edge fields, from novel therapeutics to advanced diagnostics, aiming to improve patient outcomes globally.
We are thrilled to close Fund IV and continue our mission of investing in transformative healthcare solutions,
a spokesperson for Catalio stated. This fundraise reflects strong investor confidence in the firm’s vision and track record of delivering value through strategic investments.
The healthcare investment landscape remains highly competitive, with growing interest in technologies that promise to tackle complex challenges. Catalio’s ability to secure over $400 million amidst such a dynamic environment highlights its strong market position and the trust placed in its leadership.
As Catalio Capital deploys Fund IV, industry observers anticipate a wave of innovation that could redefine standards of care. With a focus on scalability and impact, the firm is poised to play a pivotal role in shaping the future of healthcare and biotechnology in the years ahead.
Andrew Lee
